Table 1.
Clinical profiles of the participants in the study.
| Parameters | SBMA (1) | ALS (2) | Control (3) |
P-value |
||
|---|---|---|---|---|---|---|
| 1 vs. 3 | 2 vs. 3 | 1 vs. 2 | ||||
| No. | 32 | 37 | 30 | |||
| Age, year (range) | 50.09 ± 9.42 (36.00–70.00) | 49.95 ± 8.85 (31.00–69.00) | 48.30 ± 10.92 (33.00–73.00) | >0.05 | >0.05 | >0.05 |
| Height (cm) | 171.22 ± 4.98 | 171.59 ± 5.52 | 171.70 ± 4.29 | >0.05 | >0.05 | >0.05 |
| Duration, year (range) | 8.83 ± 6.90 (2.00–30.00) | 1.24 ± 0.81 (0.17–4.00) | NA | NA | NA | <0.001 |
| Total MRC score | 78.66 ± 8.67 (58.00–90.00) | 76.30 ± 9.66 (51.00–90.00) | NA | NA | NA | 0.377 |
| Upper limb MRC score | 51.19 ± 6.58 (36.00–60.00) | 48.65 ± 8.78 (30.00–60.00) | NA | NA | NA | 0.241 |
| Lower limb MRC score | 27.47 ± 2.87 (22.00–30.00) | 28.19 ± 2.86 (21.00–30.00) | NA | NA | NA | 0.225 |
ALS, amyotrophic lateral sclerosis; SBMA, spinobulbar muscular atrophy; NA, not applicable. Values are mean ± SD. Values with significant differences printed in bold characters. For comparisons of parameters between the SBMA patients, the ALS patients, and the normal controls, Bonferroni adjustment was used and α’ < 0.0167 was considered statistically significant.